Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July 2024. With its earlier launch, much of the real-world data at AD/PD ...

Ralph Carmona, a 74-year-old Portland man who has Alzheimer's, says he is a living example of the value of medical research.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's patients.